頁籤選單縮合
題名 | Single-Center Experience with Overlapping Paclitaxel-Eluting Stent for Diffuse Coronary Lesions= |
---|---|
作者 | Chen, Michael Yu-chih; Wang, Ji-hung; |
期刊 | Acta Cardiologica Sinica |
出版日期 | 20100300 |
卷期 | 26:1 2010.03[民99.03] |
頁次 | 頁7-11 |
分類號 | 415.3161 |
語文 | eng |
關鍵詞 | Angioplasty; Coronary heart disease; Drug eluting stent; |
英文摘要 | Background: Treatment of long, de novo coronary lesions with single drug-eluting stent is associated with very low rate of target lesion revascularization and other major adverse cardiac events. However, safety and efficacy of using multiple overlapping drug-eluting stents in patients with diffuse coronary artery lesions remain unclear. We reported the clinical and angiographic outcomes of overlapping paclitaxel-eluting stents at 9 months post-implantation in our mstltution. Methods: From April 2004 to November 2007, we evaluated fifty-one consecutive patients who required overlapping pac1itaxel-eluting stents for diffuse, de novo coronary lesions (> 20 mm). A retrospective chart review was conducted at the end of9 months to identify any major adverse cardiac events during the 9-month period after the procedure. Result: The study population consisted of fifty-one patients and included 60.8% of the cases with diabetes mellitus (60.8%) and 32 cases with triple-vessel disease (62.7%). The number of stents implanted per patient was 2.1±0.3, and the mean total stent length was 56.5±12.1 mm. Procedural success was achieved in 100% of the cases. No patients had in-hospital Q-wave myocardial infarction, intraprocedural stent thrombosis or death. Forty-five patients (88%) were available for clinical follow-up, and 28 patients (54.9%) had an angiographic follow-up during the 9-month period. One patient died of non-cardiac cause, three patients underwent target lesion revascularization (6.7%) and four patients (8.9%) underwent target vessel revascularization after 9-month clinical follow up. The rate of major adverse cardiac events at 9 months was 8.9%. Conclusion: Overlapping paclitaxel-eluting stents are relatively safe and associated with good midterm c1inical outcomes in patients with diffuse coronary lesions. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。